TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SW1WRJ8
| Market Closed - Deutsche Boerse AG 01:08:25 18/05/2024 am IST | ||
| 20.99 EUR | -1.92% |
|
| Current month | -19.73% | ||
| 1 month | -19.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 20.99 | -1.92% |
| 16/24/16 | 21.4 | -1.52% |
| 15/24/15 | 21.73 | -4.02% |
| 14/24/14 | 22.64 | +0.22% |
| 13/24/13 | 22.59 | -2.88% |
Delayed Quote Deutsche Boerse AG
Last update May 18, 2024 at 01:08 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SW1WRJ |
| ISIN | DE000SW1WRJ8 |
| Date issued | 04/08/2023 |
| Strike | 671.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 28.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.34 € |
|---|---|
| Lowest since issue | 20.72 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
